Trade Star Investment Holding Group Co., Ltd. Held an ‘Ademetionine’ Release Conference and a Customer Appreciation Meeting in Kunming
In the afternoon of July 24, 2014 which is just the day before the opening of 49th Newdrugs China the Trade Star Investment Holding Group held an ‘Ademetionine’ release conference and a customer appreciation meeting in the VIP conference hall, floor 3, Empark Grand Hotel Kunming.
The general manager of Zhejiang Zhenyuan Pharmaceutical Co., Ltd. Weiming Fan, the general manager of Harbin Medical University Pharmaceutical Co., Ltd Yongqiang Wang as well as many other industry leaders had taken part in the conference.
It was raining that day but still hadn’t dampened the customers’ enthusiasm which can be told by the packed hall.
At first, the Group’s CEO Chao LEE made an address and shared the successful experience of Trade Star (delicacy management, operation strategy of large species) and looking forward to the long-range development direction— to become a listed company.
The general manager of Zhejiang Zhenyuan Pharmaceutical Co., Ltd. Mr. Weiming Fan introduced the cooperation history with our company to research and develop the ‘Ademetionine’ and expressed the hope that both parties can strive for a sustained cooperation and continue to strengthen the brand to become the main medicine in treating the liver disease.
The vice general manager of the subsidiary Yunnan Yongan Pharmaceutical Co., Ltd. Mr. Bin Wang introduced the cooperation process between Yongan and Trade Star. Then he illustrated the company’s future development direction.
The Group’s assistant president and marketing director Mr. Yong Tao interpreted comprehensively about the clinical value, market value, research and development technology as well as other aspects of the Ademetionine 1,4-butanedisulfonate for injection.